PUMA BIOTECHNOLOGY INC (PBYI)
US74587V1070 - Common Stock
We assign a fundamental rating of 5 out of 10 to PBYI. PBYI was compared to 564 industry peers in the Biotechnology industry. PBYI has an average financial health and profitability rating. PBYI is valued quite cheap, but it does not seem to be growing. This makes PBYI very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PBYI was profitable.
In the past year PBYI had a positive cash flow from operations.
PBYI had negative earnings in 4 of the past 5 years.
Of the past 5 years PBYI 4 years had a positive operating cash flow.
1.2 Ratios
PBYI's Return On Assets of 10.53% is amongst the best of the industry. PBYI outperforms 96.23% of its industry peers.
Looking at the Return On Equity, with a value of 32.69%, PBYI belongs to the top of the industry, outperforming 98.56% of the companies in the same industry.
PBYI has a Return On Invested Capital of 23.20%. This is amongst the best in the industry. PBYI outperforms 99.10% of its industry peers.
PBYI had an Average Return On Invested Capital over the past 3 years of 11.31%. This is below the industry average of 13.83%.
The 3 year average ROIC (11.31%) for PBYI is below the current ROIC(23.20%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.53% | ||
| ROE | 32.69% | ||
| ROIC | 23.2% |
ROA(3y)-1.16%
ROA(5y)-12.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)11.31%
ROIC(5y)N/A
1.3 Margins
PBYI has a better Profit Margin (9.54%) than 94.79% of its industry peers.
With an excellent Operating Margin value of 13.30%, PBYI belongs to the best of the industry, outperforming 95.51% of the companies in the same industry.
PBYI has a better Gross Margin (69.29%) than 82.76% of its industry peers.
In the last couple of years the Gross Margin of PBYI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.3% | ||
| PM (TTM) | 9.54% | ||
| GM | 69.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.82%
GM growth 5Y-3.17%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PBYI is creating value.
The number of shares outstanding for PBYI has been increased compared to 1 year ago.
The number of shares outstanding for PBYI has been increased compared to 5 years ago.
PBYI has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -6.04, we must say that PBYI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.04, PBYI is not doing good in the industry: 66.79% of the companies in the same industry are doing better.
The Debt to FCF ratio of PBYI is 2.32, which is a good value as it means it would take PBYI, 2.32 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.32, PBYI belongs to the best of the industry, outperforming 94.79% of the companies in the same industry.
PBYI has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
PBYI's Debt to Equity ratio of 0.46 is on the low side compared to the rest of the industry. PBYI is outperformed by 73.25% of its industry peers.
Even though the debt/equity ratio score it not favorable for PBYI, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.32 | ||
| Altman-Z | -6.04 |
ROIC/WACC1.93
WACC12.01%
2.3 Liquidity
A Current Ratio of 1.42 indicates that PBYI should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.42, PBYI is doing worse than 82.41% of the companies in the same industry.
PBYI has a Quick Ratio of 1.40. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PBYI (1.40) is worse than 81.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.4 |
3. Growth
3.1 Past
PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 500.00%, which is quite impressive.
The Revenue has been growing slightly by 6.29% in the past year.
The Revenue has been decreasing by -1.26% on average over the past years.
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%241.67%
Revenue 1Y (TTM)6.29%
Revenue growth 3Y1.54%
Revenue growth 5Y-1.26%
Sales Q2Q%43.49%
3.2 Future
Based on estimates for the next years, PBYI will show a very negative growth in Earnings Per Share. The EPS will decrease by -18.46% on average per year.
Based on estimates for the next years, PBYI will show a decrease in Revenue. The Revenue will decrease by -3.88% on average per year.
EPS Next Y-33.41%
EPS Next 2Y-13.21%
EPS Next 3Y-11.75%
EPS Next 5Y-18.46%
Revenue Next Year-5.79%
Revenue Next 2Y-6.48%
Revenue Next 3Y-4.55%
Revenue Next 5Y-3.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.15, the valuation of PBYI can be described as very cheap.
PBYI's Price/Earnings ratio is rather cheap when compared to the industry. PBYI is cheaper than 98.92% of the companies in the same industry.
When comparing the Price/Earnings ratio of PBYI to the average of the S&P500 Index (27.41), we can say PBYI is valued rather cheaply.
A Price/Forward Earnings ratio of 8.51 indicates a reasonable valuation of PBYI.
98.20% of the companies in the same industry are more expensive than PBYI, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.69. PBYI is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.15 | ||
| Fwd PE | 8.51 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBYI indicates a rather cheap valuation: PBYI is cheaper than 99.28% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PBYI is valued cheaply inside the industry as 99.64% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.3 | ||
| EV/EBITDA | 2.2 |
4.3 Compensation for Growth
The decent profitability rating of PBYI may justify a higher PE ratio.
A cheap valuation may be justified as PBYI's earnings are expected to decrease with -11.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.21%
EPS Next 3Y-11.75%
5. Dividend
5.1 Amount
PBYI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PUMA BIOTECHNOLOGY INC
NASDAQ:PBYI (1/3/2025, 8:00:02 PM)
After market: 3.056 +0.11 (+3.59%)2.95
-0.17 (-5.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners63.5%
Inst Owner Change-5.44%
Ins Owners15.06%
Ins Owner Change-1.1%
Market Cap144.82M
Analysts47.5
Price Target4.42 (49.83%)
Short Float %7.53%
Short Ratio5.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.29%
Min EPS beat(2)14.63%
Max EPS beat(2)31.95%
EPS beat(4)3
Avg EPS beat(4)21.6%
Min EPS beat(4)-14.94%
Max EPS beat(4)54.75%
EPS beat(8)6
Avg EPS beat(8)62.52%
EPS beat(12)10
Avg EPS beat(12)230.46%
EPS beat(16)12
Avg EPS beat(16)185.43%
Revenue beat(2)2
Avg Revenue beat(2)7.51%
Min Revenue beat(2)3.3%
Max Revenue beat(2)11.71%
Revenue beat(4)3
Avg Revenue beat(4)3.96%
Min Revenue beat(4)-3.76%
Max Revenue beat(4)11.71%
Revenue beat(8)6
Avg Revenue beat(8)3.92%
Revenue beat(12)9
Avg Revenue beat(12)5.64%
Revenue beat(16)10
Avg Revenue beat(16)5.24%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-74.24%
EPS NY rev (1m)0%
EPS NY rev (3m)15.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.15 | ||
| Fwd PE | 8.51 | ||
| P/S | 0.59 | ||
| P/FCF | 4.3 | ||
| P/OCF | 4.29 | ||
| P/B | 2.04 | ||
| P/tB | 8.26 | ||
| EV/EBITDA | 2.2 |
EPS(TTM)0.48
EY16.27%
EPS(NY)0.35
Fwd EY11.74%
FCF(TTM)0.69
FCFY23.26%
OCF(TTM)0.69
OCFY23.32%
SpS4.96
BVpS1.45
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.53% | ||
| ROE | 32.69% | ||
| ROCE | 29.37% | ||
| ROIC | 23.2% | ||
| ROICexc | 188.21% | ||
| ROICexgc | N/A | ||
| OM | 13.3% | ||
| PM (TTM) | 9.54% | ||
| GM | 69.29% | ||
| FCFM | 13.83% |
ROA(3y)-1.16%
ROA(5y)-12.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)11.31%
ROIC(5y)N/A
ROICexc(3y)35.73%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)14.31%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.82%
GM growth 5Y-3.17%
F-Score5
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.32 | ||
| Debt/EBITDA | 0.74 | ||
| Cap/Depr | 0.69% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 2.84 | ||
| Cash Conversion | 76.8% | ||
| Profit Quality | 144.96% | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z | -6.04 |
F-Score5
WACC12.01%
ROIC/WACC1.93
Cap/Depr(3y)62.74%
Cap/Depr(5y)78.39%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%241.67%
EPS Next Y-33.41%
EPS Next 2Y-13.21%
EPS Next 3Y-11.75%
EPS Next 5Y-18.46%
Revenue 1Y (TTM)6.29%
Revenue growth 3Y1.54%
Revenue growth 5Y-1.26%
Sales Q2Q%43.49%
Revenue Next Year-5.79%
Revenue Next 2Y-6.48%
Revenue Next 3Y-4.55%
Revenue Next 5Y-3.88%
EBIT growth 1Y13.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.56%
EBIT Next 3Y-19.19%
EBIT Next 5YN/A
FCF growth 1Y216.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y216.65%
OCF growth 3Y227.35%
OCF growth 5YN/A